After at least eight auditions, "Jeopardy!" superfan Harvey Silikovitz learned he was chosen to compete on the show. What he ...

In the future, therapies that focus on gut health—whether through diet, medication, or nerve stimulation—could be used to ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

One of the world’s leading Parkinson’s disease scientists has warned of a potential pandemic of the neurological condition if research doesn’t “step up” to address the looming crisis.

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

Meiragtx's AAV-GAD program for Parkinson's disease is phase 3 ready, with positive data from a randomized, sham-controlled ...

As World Sleep Day comes around, it seems everybody is talking about how they manage to doze off, and it turns out there ...

Hologen is paying MeiraGTx $200 million upfront and committing $230 million to fund Hologen Neuro AI and a Parkinson's disease gene therapy.

Researchers say structure reveals many new ways to change PINK1, essentially switching it on, which will be "life-changing" for people with Parkinson’s disease.